Abstracts Archive - Page 1262 of 2425 - ACR Meeting Abstracts

Abstract Number: 847 • 2017 ACR/ARHP Annual Meeting
The Mediational Role of Helplessness in Psychological Outcomes in Systemic Lupus Erythematosus
Desiree R Azizoddin¹, Sarah D. Mills², Perry M. Nicassio³, Geraldine Zamora Racaza⁴ and Michael Weisman⁵, ¹1611 W Harrison, 1611 W Harrison, Chicago, IL, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³Cousins Center for PNI, UCLA, LA, CA, ⁴Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease affecting multiple organs, leading to a significant impact on health-related quality of life. Theoretical models…
Abstract Number: 848 • 2017 ACR/ARHP Annual Meeting
“Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!” Different Perspectives of Individuals on Predictive Testing – Results of an International Qualitative Interview Study
Erika Mosor¹, Michaela Stoffer², Günter Steiner³, Karim Raza⁴, Rebecca J Stack⁴, Gwenda Simons⁴, Marie Falahee⁴, Georg Schett⁵, Matthias Englbrecht⁶, Josef S. Smolen², Axel J. Hueber⁶ and Tanja Stamm⁷, ¹Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, University of Birmingham and Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK, Birmingham, United Kingdom, ⁵Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Vienna, Austria
Background/Purpose: People at risk of developing rheumatoid arthritis (RA) may be candidates for interventions aimed at preventing RA development [1]. The identification of such at…
Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Iago Pinal-Fernandez¹, Berta Ferrer-Fabregas², Ernesto Trallero-Araguas¹, Eva Balada¹, Maria Angeles Martinez³, Jose Cesar Milisenda⁴, Gloria Aparicio-Español⁵, Moises Labrador-Horrillo¹, Vicente Garcia-Patos¹, Josep Maria Grau-Junyent⁴ and Albert Selva O'Callaghan⁶, ¹Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, ²Pathology, Vall d´Hebron, Barcelona, Spain, ³Immunology, Immunology Department, Barcelona, Spain, ⁴Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, ⁵Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, ⁶Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…
Abstract Number: 850 • 2017 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System
Xerxes Pundole, Mohsin Shah, Noha Abdel-Wahab and Maria Suarez-Almazor, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Immune checkpoint inhibitors have become standard of care for many malignancies. Although these therapies are effective, they can activate the immune system resulting in…
Abstract Number: 851 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Predict Long Term Survival in Myositis Associated Interstitial Lung Disease
Silvia Martinez¹, Rohit Aggarwal^2,3 and Chester V. Oddis⁴, ¹Internal Medicine, UPMC, pittsburgh, PA, ²Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Interstitial lung disease (ILD) significantly contributes to morbidity and mortality in adult polymyositis (PM) and dermatomyositis (DM). Myositis associated autoantibodies (MAA) are associated with…
Abstract Number: 852 • 2017 ACR/ARHP Annual Meeting
RNAseq Detection of Gene Dysregulation in PBMCs from Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody
Chiang-Ching Huang¹, Victoria Hans², Dong Xu³, Megan L. Curran^4,5, Gabrielle A. Morgan⁶, Elisha D.O. Roberson⁷ and Lauren M. Pachman^8,9, ¹Biostatistics, Joseph J. Zilber School of Public Health,, Milwaukee, WI, ²CureJM Center of Excellence, Stanly Manne Research Center, Chicago, IL, ³Pediatric Rheumatology, Stanley Manne Research Center, Chicago, IL, ⁴Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁷Depts. of Medicine and Genetics, Division of Rheumatology, Washington University, St. Louis, MO, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Children with Juvenile Dermatomyositis (JDM) have variable responses to the available immunosuppressive drugs, with less than optimal outcomes, making it essential to characterize their…
Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Alexander Oldroyd^1,2, Jamie C Sergeant^1,3, Paul New⁴, Neil J. McHugh^5,6, Zoe Betteridge⁵, Janine Lamb⁷, William Ollier⁷, Robert Cooper^4,7,8 and Hector Chinoy^2,9, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴MRC/ARUK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, United Kingdom, ⁵Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ⁷Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁹Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 855 • 2017 ACR/ARHP Annual Meeting
Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo
Peter C. Taylor¹, Roy Fleischmann², Elizabeth Perkins³, Jeffrey Lisse⁴, Baojin Zhu⁴, Carol L Gaich⁴, Xiang Zhang⁴, Douglas E. Schlichting⁴, Christina L. Dickson⁴ and Tsutomu Takeuchi⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Rheumatology, Rheumatology Care Center, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Assessment of pain improvement during treatment for rheumatoid arthritis (RA) may help frame patient expectations and may be useful to clinical decision-making and discussions…
Abstract Number: 856 • 2017 ACR/ARHP Annual Meeting
Trends and Predictors of Chronic Opioid Use in Individuals with RA
Yvonne C. Lee¹, Joel Kremer², Hongshu Guan³, Jeffrey D Greenberg⁴ and Daniel H. Solomon⁵, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²The Center for Rheumatology, Albany Medical College, Albany, NY, ³Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴NYU School of Medicine, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The opioid epidemic is a major public health concern, requiring urgent action. However, little is known about chronic opioid use among individuals with RA.…
Abstract Number: 857 • 2017 ACR/ARHP Annual Meeting
Relation of Pain Sensitization to Low Physical Function: The Multicenter Osteoarthritis Study
Joshua Stefanik^1,2, Daniel White³, Carrie Brown⁴, Laura Frey-Law⁵, Michael Nevitt⁶, Cora E. Lewis⁷ and Tuhina Neogi², ¹Physical Therapy, Northeastern University, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Department of Physical Therapy, University of Delaware, Newark, DE, ⁴Boston University School of Public Health, Boston, MA, ⁵University of Iowa, Iowa City, IA, ⁶Department of Epidemiology & Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA, ⁷University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Peripheral and central sensitization (alterations in pain signaling) are related to heightened pain severity and can be present in knee osteoarthritis (OA). Sensory input…
Abstract Number: 858 • 2017 ACR/ARHP Annual Meeting
Identification of Clinically Relevant Pain Profiles in Individuals with Active RA
Alyssa Wohlfahrt¹, Zhi Zhang¹, Bing Lu², Clifton O. Bingham III³, Marcy B. Bolster⁴, Wendy Marder⁵, Larry W. Moreland⁶, Kristine Phillips⁷, Tuhina Neogi⁸ and Yvonne C. Lee⁹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ⁸Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Despite DMARD treatment, many RA patients continue to suffer from pain. Defining distinct pain phenotypes may advance the use of therapies targeted at specific…
Abstract Number: 859 • 2017 ACR/ARHP Annual Meeting
Identifying Pain Susceptibility Phenotypes in Those Free of Knee Pain with or at Risk for Knee Osteoarthritis and Their Relation to Developing Knee Pain
Lisa Carlesso¹, Neil Segal², Laura Frey-Law³, Yuqing Zhang⁴, Na Lu⁵, Cora E. Lewis⁶, Michael C. Nevitt⁷ and Tuhina Neogi⁵, ¹School of Rehabilitation, Université de Montréal, Montreal, QC, Canada, ²University of Kansas, Shawnee, KS, ³UIowa, Iowa City, IA, ⁴Clinical Edpidemiology Reserach and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁶University of Alabama Birmingham, Birmingham, AL, ⁷Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA
Background/Purpose: It is well recognized that factors beyond structural features contribute to the pain experience in people with knee osteoarthritis (OA). Independent of structural pathology,…
Abstract Number: 860 • 2017 ACR/ARHP Annual Meeting
Effective Treatment of Persistent Arthritis Pain Requires Co-Modulation of TNF and Type I Interferon
Sarah Woller¹, Tony Yaksh² and Maripat Corr³, ¹Anesthesiology, UCSD, La Jolla, CA, ²Anesthesiology 0818, UCSD, La Jolla, CA, ³Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA
Background/Purpose: Pain persisting beyond the resolution or control of clinical signs of rheumatoid arthritis (RA) decreases quality of life for millions of people. Unfortunately, this…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].